FOPO nets $40.5mm for Five Prime
Five Prime Therapeutics Inc. (therapies for cancer and inflammatory diseases) netted $40.5mm through the follow-on public offering of 3.45mm common shares (including the overallotment) at $12.50 each. Some of the funds will support ongoing clinical trials of its CSF1R antibody FPA008 for autoimmune disease, and to move preclinical FPA144, an FGFR2b antibody for gastric cancer, into the clinic.
Drug Discovery Tools
- Large Molecule
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com